Introduction {#sec1-1}
============

Methamphetamine (METH) is an illicit and potent psychostimulant, widely abused by over 35 million people worldwide, which can cause numerous adverse effects on the central nervous system (Tallóczy et al., 2008). With repeated high doses of METH, animals initially experience hyperexcitability, followed by pacing, checking, sniffing, exploration, and loss of food intake. Evidence suggests that the behavioral alterations are persistent and correlate with neuron damage (Scott et al., 2007). Redistribution of dopamine from synaptic vesicles to cytoplasmic compartments and the consequent elevation of oxidizable dopamine concentrations may be primarily responsible for dopamine terminal damage by METH (Cubells et al., 1994). The substantial METH-induced release of dopamine from vesicles to cytosol with the resulting formation of toxic reactive oxygen species, such as superoxide and hydroxyl radicals, are well documented in both *in vivo* (Giovanni et al., 1995) and *in vivo* (Cubells et al., 1994) studies. Together, this evidence clearly indicates that oxidative stress following administration of METH is the major determinant in METH-induced neuronal impairment. It has also been noted that rats given METH show the same depletion seen in Parkinson\'s disease (PD) (Callaghan et al., 2010).

PD is the second most common neurodegenerative disorder, affecting 1--2% of the general population over 60 years of age (Olanow et al., 2009), and is characterized by neuropathology consisting of progressive loss of substantia nigra neurons. Intracellular proteinaceous inclusions, known as Lewy bodies, are also found in PD, and consist largely of α-synuclein, a small acidic protein susceptible to misfolding and aggregation (Leong et al., 2009). Several lines of evidence have shown that α-synuclein accumulation in Lewy bodies, and genomic multiplications and missense mutations of α-synuclein, cause early-onset PD, indicating that α-synuclein has a critical role in the etiology of this disease (Hardy et al., 2009; Devine et al., 2011). Recent investigations emphasize the importance of α-synuclein levels in PD, showing that higher levels are able to cause neuronal dysfunction and disease. An increasing number of studies show that elevated expression of α-synuclein is observed after METH administration, in animals (Fornai et al., 2005) and in cells (Ajjimaporn et al., 2005). Oxidative modifications of α-synuclein and generation of stable oligomers contribute to the neurotoxicity of oxidative stress (Norris et al., 2003). In a previous study, we showed that α-synuclein knockdown attenuated METH-induced neurotoxicity *in vitro* (Chen et al., 2013). The present study investigates the protective mechanism of α-synuclein knockdown in rat striatum against METH intoxication.

Materials and Methods {#sec1-2}
=====================

Preparation of viral vector {#sec2-1}
---------------------------

The shRNA sequence targeting α-synuclein (Liu et al., 2012) was designed as follows: 5′-CGC GTC CCC GGA AGA TAT GCC TGT GGA TCC **TTC AAG AGA** GGA TCC ACA GGC ATA TCT TCC TTT TTG GAA AT-3′; its efficacy has been demonstrated previously (Sapru et al., 2006). The shRNA was cloned into a pLVTHM retrovirus vector (Addgene, Cambridge, MA, USA). Retrovirus (titer: 1 × 10^9^ TU/mL) was obtained using transfected 293T cells (Liu et al., 2012).

Animal grouping and α-synuclein knockdown in the right striatum of METH intoxicated rats {#sec2-2}
----------------------------------------------------------------------------------------

A total of 60 adult male specific pathogen-free Wistar rats, 8 weeks old, weighing 220--240 g, were purchased from the Experimental Animal Center of Southern Medical University, China (certificate No. SCXK (Yue) 2006-0015). Animals were housed in a standard laboratory environment (25 ± 2°C, 60--70% humidity, 12 hour light/dark cycle) with *ad libitum* access to food and water. Rats were housed and habituated for 1 week before the experiments started. All procedures complied with the Guidelines for the Care and Use of Experimental Animals and were approved by the Animal Care and Use Committee of Southern Medical University, China.

The rats were randomly and equally divided into four groups: control (saline, saline), model (saline, METH), empty vector (empty vector, METH), and RNAi (shRNA-α-synuclein lentivirus, METH). All rats were housed in solitary cages. Animals were anesthetized with 10% chloral hydrate (350 mg/kg) and placed in a stereotaxic frame (Stoelting Company, Wisconsin, USA) with the tooth bar set at 0.0 mm. Rats in the control and model groups were injected with physiological saline (10 μL/rat). The empty vector group and RNAi group were injected with empty vector (10 μL/rat) and shRNA-α-synuclein lentivirus (10 μL/rat), respectively. Lentivirus or physiological saline was injected stereotaxically into the right striatum (Connor et al., 1999) using a 10-μL Hamilton syringe (Hamilton Company, Reno, NV, USA) with a 30-gauge needle at a rate of 0.5 μL/min. Injection coordinates were 1.6 mm rostral, 3.8 mm lateral and 5.5 mm ventral to bregma (Sapru et al., 2006). The needle was retained in place for 5 minutes before being withdrawn at 1 mm/min.

METH (C~6~H~5~-CH~2~-CH(CH~3~)-NH-CH~3~, molecular weight 149, solid, purity \> 99.1%) was purchased from the National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China) and dissolved in physiological saline. At 2 weeks after injection of lentivirus or saline, rats in the model group, empty vector group and RNAi group received eight injections of METH (15 mg/kg intraperitoneally, in 1 mL solution) at 12-hour intervals, and control rats received physiological saline (1 mL intraperitoneally) on the same schedule as METH. Body weight, food intake and water intake were measured daily after the first injection. At 24 hours after the final injection, rats were anesthetized and perfused transcardially with 0.9% saline. The brains were removed and the striatum was separated out for neurochemical analyses.

Quantitative real-time PCR analysis of α-synuclein mRNA expression in rat striatum {#sec2-3}
----------------------------------------------------------------------------------

The right rat striatum was frozen in liquid nitrogen and crushed using a pestle and mortar. Total RNA was extracted using TRIzol reagent according to the manufacturer\'s instructions. Reverse transcription reactions were carried out using 1 μg of total RNA and the PrimeScript™ RT reagent kit (Takara Biotechnology, Dalian, Liaoning Province, China). Quantitative real-time PCR was performed using the SYBR Green quantitative real-time PCR kit (Takara Biotechnology) and the following gene-specific primers: β-actin, forward: 5′-CCC ATC TAT GAG GGT TAC GC-3′, reverse: 5′-TTT AAT GTC ACG CAC GAT TTC-3′; α-synuclein, forward: 5′-CAA AGG CCA AGG AGG GAG TT-3′, reverse: 5′-CCT CCA CTG TCT TCT GAG CG-3′. 2^-ΔΔCt^ normalization was used and quantitative real-time PCR was analyzed using ABI 7500 software V2.0.5 (Applied Biosystems, Carlsbad, CA, USA).

Western blot analysis of α-synuclein expression {#sec2-4}
-----------------------------------------------

Whole right striatum tissue protein extracts were resolved by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene difluoride membranes. The membranes were incubated overnight at 4°C with primary antibody at the following dilutions: rabbit anti-α-synuclein polyclonal antibody (1:1,000; Cell Signaling Technology, Danvers, MA, USA); rabbit anti-β-actin polyclonal antibody (1:1,000; Cell Signaling Technology). Following 1 hour of incubation at room temperature with corresponding horseradish peroxidase-conjugated goat anti-rabbit IgG (1:5,000; Cell Signaling Technology), the membrane was developed with Chemiluminescence ECL Plus Western Blotting detection reagents (Amersham Biosciences, Piscataway, NJ, USA). Densitometric analysis was carried out to determine the protein content in each band on the membrane, using Image J software (National Institutes of Health, Bethesda, MD, USA). Each western blot reproduced here is typical of at least three separate experiments.

Assessment of stereotyped behavior score {#sec2-5}
----------------------------------------

At 2 weeks after METH injection, stereotyped behavior score was assessed according to the standard method reported by Sams-Dodd (Seiden and Vosmer, 1984).

Enzyme-linked immunosorbent assay (ELISA) for dopamine and tyrosine hydroxylase {#sec2-6}
-------------------------------------------------------------------------------

Dopamine and tyrosine hydroxylase levels were measured in homogenized striatum using ELISA kits (R & D Systems, Boston, MA, USA), according to the manufacturer\'s instructions. The color was read in a microtiter plate reader (BioTek Company, Winooski, Vermont, USA) at 450 nm. Sample concentration was calculated using a standard curve of known concentrations of dopamine and tyrosine hydroxylase.

Assay of reactive oxygen species {#sec2-7}
--------------------------------

Homogenized striatum was stained with the oxidant-sensitive dye CM-H~2~ DCFDA, and reactive oxygen species levels were determined using a reactive oxygen species detection kit (Genmed Scientifics Inc., Shanghai, China) according to the manufacturer\'s protocol. Fluorescence was measured using a microtiter spectrofluorometer (Shimadzu Corporation, Kyoto, Japan) at 490 and 530 nm. Data were obtained as relative fluorescence units after background subtraction. Relative fluorescence units for untreated controls for each assay were averaged and the values for each treated sample were normalized to this average, followed by statistical analyses.

Determination of levels of nitrogen monoxide and malondialdehyde and activities of nitric oxide synthase and superoxide dismutase {#sec2-8}
---------------------------------------------------------------------------------------------------------------------------------

Levels of nitrogen monoxide and malondialdehyde and activities of nitric oxide synthase and superoxide dismutase in rat striatum were measured using kits (Nanjing Jiancheng Bioengineering Institute, Nanjing, Jiangsu Province, China), according to the manufacturer\'s instructions. Color was read in a microtiter spectrophotometer at 550, 532, 530, and 550 nm, respectively.

Neuronal apoptosis detection using TUNEL staining {#sec2-9}
-------------------------------------------------

To confirm the presence of cell death by an apoptotic-like mechanism following exposure to METH, we used the TUNEL Apoptosis Detection biotin-labeled POD Kit (Genscript Corporation, Piscataway, NJ, USA) according to the manufacturer\'s protocol. Images were obtained using a laser confocal microscope (Olympus, Tokyo, Japan); TUNEL-positive neurons appeared green. Cell nuclei were stained blue with 4′,6-diamidino-2-phenylindole (DAPI). Apoptotic rate was expressed by normalizing the number of TUNEL-positive cells in six separate but equal visual fields to the total cell number in the corresponding areas in each sample.

Statistical analysis {#sec2-10}
--------------------

All values are expressed as mean ± SD. Statistical analysis was performed using one-way analysis of variance (ANOVA) and repeated measures ANOVA using SPSS version 13.0 software (SPSS, Chicago, IL, USA). Multiple comparisons were performed using the least significant difference and Student-Newman-Keuls *post-hoc* tests. A value of *P* \< 0.05 was considered statistically significant.

Results {#sec1-3}
=======

α-Synuclein-shRNA downregulated α-synuclein expression in the striatum of rats with METH intoxication {#sec2-11}
-----------------------------------------------------------------------------------------------------

To inhibit the expression of α-synuclein in the rat striatum, we injected α-synuclein-shRNA lentivirus into the rat striatum. We tested striatal mRNA and protein levels using quantitative real-time PCR and western blot analysis. Compared with the control group, the model group showed significantly greater α-synuclein mRNA and protein expression after METH treatment (*P* \< 0.05; [**Figure 1**](#F1){ref-type="fig"}). In contrast, there was no significant difference in the expression of α-synuclein mRNA or protein between the model group and empty vector group (*P* \> 0.05; [**Figure 1**](#F1){ref-type="fig"}). α-Synuclein mRNA and protein expression was significantly lower in striatal injected with α-synuclein-shRNA lentivirus (RNAi group) than in striatum from the model group (*P* \< 0.05; [**Figure 1**](#F1){ref-type="fig"}).

![Effect of α-synuclein-shRNA on α-synuclein mRNA and protein expression in the striatum of rats with methamphetamine intoxication.\
(A) The mRNA expression of α-synuclein in rat striatum, analyzed by quantitative real-time PCR. (B) Protein expression of α-synuclein in rat stri-atum, analyzed by western blot. Data are presented as mean ± SD of five rats in each group and analyzed using one-way analysis of variance with least significant difference *post-hoc* test. \**P* \< 0.05, *vs*. control group; \#*P* \< 0.05, *vs*. model group.](NRR-9-951-g001){#F1}

α-Synuclein knockdown improved METH-induced abnormal behavior {#sec2-12}
-------------------------------------------------------------

We measured body weight and intake of food and water to assess the effect of α-synuclein knockdown on the animals' condition during repeated, high dose METH treatments. Food intake and body weight of the model group rats were significantly lower after METH treatment compared with the control group (*P* \< 0.05). In contrast, no difference was found in either food intake or body weight between the model and empty vector groups (*P* \> 0.05). Food intake and body weight of rats in the RNAi group were markedly greater than those of model group rats (*P* \< 0.05; **Figure [2A](#F2){ref-type="fig"}, [C](#F2){ref-type="fig"}**). We also found that water intake of the model group rats was considerably higher than that of control rats (*P* \< 0.05), and rats in the RNAi group drank less water than those in the model group (*P* \< 0.05; [**Figure 2B**](#F2){ref-type="fig"}). We also measured stereotyped behavior. Compared with control rats, stereotyped behavior in model group rats was noticeably greater after METH treatment (*P* \< 0.05). There was no change in the stereotyped behavior score between the model and empty vector groups (*P* \> 0.05). The stereotyped behavior score of RNAi group rats was markedly lower than that in model group rats (*P* \< 0.05; [**Figure 2D**](#F2){ref-type="fig"}).

![Effect of α-synuclein knockdown on methamphetamine-induced abnormal behavior.\
(A) Food intake. (B) Water intake. (C) Body weight. (D) Stereotyped behavior. 1--8: Stereotyped behavior scores from the first to the eighth assess-ments. Each assessment was performed at 10 minutes after the injection at 8:00 and 18:00, total eight assessments, for 4 days. According to the stan-dard stereotyped behavior score (Seiden and Vosmer, 1984), the lower the score, the better the rats' survival condition. Data are presented as mean ± SD of ten rats for each group. Repeated measures analysis of variance and least significant difference tests were used. \**P* \< 0.05, *vs*. control group; \#*P* \< 0.05, *vs*. model group.](NRR-9-951-g002){#F2}

Knockdown of α-synuclein reversed the reduction in dopamine level and tyrosine hydroxylase activity caused by METH {#sec2-13}
------------------------------------------------------------------------------------------------------------------

Dopamine level and tyrosine hydroxylase activity were lower in the striatum of model group rats compared with those in the control group (*P* \< 0.05; [**Figure 3**](#F3){ref-type="fig"}). There was no significant difference in dopamine level or tyrosine hydroxylase activity between the model and empty vector groups (*P* \> 0.05); however, in α-synuclein knockdown rats, dopamine levels and tyrosine hydroxylase activity were markedly greater than those in the model group (*P* \< 0.05; [**Figure 3**](#F3){ref-type="fig"}).

![Effect of α-synuclein knockdown on dopamine (A) and tyrosine hydroxylase (B) levels in the rat striatum.\
Data are presented as mean ± SD of eight rats in each group and analyzed using one-way analysis of variance with least significant difference *post-hoc* test. \**P* \< 0.05, *vs*. control group; \#*P* \< 0.05, *vs*. model group.](NRR-9-951-g003){#F3}

Knockdown of α-synuclein attenuated METH-induced oxidative stress {#sec2-14}
-----------------------------------------------------------------

To further identify the mechanisms underlying METH-induced oxidative stress and striatal knockdown of α-synuclein, we examined the correlative factors involved in METH-induced neurotoxicity, namely, reactive oxygen species production, nitric oxide synthase activity, nitrogen monoxide level, malondialdehyde expression and superoxide dismutase activity ([**Figure 4**](#F4){ref-type="fig"}). Upregulation of reactive oxygen species production, nitric oxide synthase activity, nitrogen monoxide level and malondialdehyde expression, and downregulation of superoxide dismutase activity, were detected in striatum of model group rats that had received METH compared with control rats (*P* \< 0.05). In contrast, no difference was found in these indicators between the model and empty vector groups (*P* \> 0.05). We also found that reactive oxygen species production, nitric oxide synthase activity, nitric oxide level and malondialdehyde expression were lower, while superoxide dismutase activity was markedly elevated, in RNAi group rats compared with model group rats (*P* \< 0.05; [**Figure 4**](#F4){ref-type="fig"}).

![Effect of α-synuclein knockdown on methamphetamine-induced oxidative stress in rat striatum.\
(A) Reactive oxygen species (ROS) level. (B) Nitric oxide synthase (NOS) activity. (C) Nitric oxide (NO) production. (D) Malondialdehyde (MDA) ex-pression. (E) Superoxide dismutase (SOD) activity. Data are presented as mean ± SD of eight rats in each group and analyzed using one-way analysis of variance with least significant difference *post-hoc* test. \**P* \< 0.05, *vs*. control group; \#*P* \< 0.05, *vs*. model group. RFU: Relative fluorescence units.](NRR-9-951-g004){#F4}

α-Synuclein knockdown decreased METH-induced neuronal apoptosis {#sec2-15}
---------------------------------------------------------------

We investigated the influence of α-synuclein knockdown on METH-induced neuronal apoptosis in rat striatum using TUNEL staining. Apoptotic cells exhibiting inter-nucleosomal DNA fragmentation were sparse in control striatum. A larger number of apoptotic cells were observed in the striata of the model and empty vector group rats when compared with control group (*P* \< 0.05). Knockdown of α-synuclein markedly reduced the number of apoptotic cells in the striatum compared with the model group (*P* \< 0.05; [**Figure 5**](#F5){ref-type="fig"}).

![Effect of α-synuclein knockdown on METH-induced neuronal apoptosis in the rat striatum.\
(A) Green TUNEL-positive cells (arrows) show apoptosis in the striatum of rats in the control (a), model (b), empty vector (c) and RNAi (d) groups. Scale bar: 50 μm. (B) Quantification of cell apoptosis in the rat striatum. Data are presented as mean ± SD of eight rats in each group and analyzed using repeated-measures analysis of variance and Student-Newman-Keuls *post-hoc* test. \**P* \< 0.05, *vs*. control group; \#*P* \< 0.05, *vs*. model group.](NRR-9-951-g005){#F5}

Discussion {#sec1-4}
==========

Many previous investigations have shown that METH markedly upregulates the expression of α-synuclein *in vivo* (Fornai et al., 2005) and *in vitro* (Ajjimaporn et al., 2007). Recently, a role for oxidative stress in the development of METH-induced neurotoxicity has been largely supported by correlative evidence, *i.e.*, increased pro-oxidant production and reduced antioxidant defense are associated with exposure to METH. The present study demonstrates that METH-induced oxidative stress correlates with the cellular level of α-synuclein. Here, we show for the first time that suppression of α-synuclein expression significantly attenuates METH-induced neurotoxicity in the rat striatum by inhibiting oxidative stress and restoring the dopaminergic system.

METH is potentially toxic to the central nervous system. It was found to induce significant nerve terminal damage in animal models (Kita et al., 2003), create persistent interference in the dopaminergic system of the brain (Volkow et al., 2001a, b), and generate structural abnormalities in the brain (Thompson et al., 2004). α-Synuclein is an unstructured soluble protein that can assemble into amyloid aggregates forming intracellular inclusion bodies called Lewy bodies, which are present in PD. Several studies indicate that overexpression of α-synuclein is found in METH-intoxicated animals, leading to the proposition of METH-induced dopaminergic toxicity as a model for PD. Thus, knockdown of α-synuclein expression has the capacity to protect against neurotoxicity in this METH-induced PD model.

To investigate the effects of α-synuclein knockdown in METH intoxicated rats, we first established α-synuclein reduction in rats using α-synuclein-shRNA lentivirus. Rats in this group (RNAi) showed markedly lower α-synuclein mRNA and protein expression in the striatum compared with model group rats. In contrast, there was no significant difference in α-synuclein mRNA and protein expression between model group and empty vector group rats. Thus, these data confirmed the effectiveness of the α-synuclein knockdown in the striatum.

METH abuse has many negative consequences in humans. Acute toxicity, altered behavioral and cognitive functions and neurological injury are observed after METH administration (Murray, 1998; Albertson et al., 1999; Barr et al., 2006; Scott et al., 2007). In the present study, we measured food and water intake, body weight and stereotyped behavior score to estimate the effect of α-synuclein knockdown on animals' survival condition during repeated high dose METH administration. Compared with the control group, the body weight and food intake of rats in the model group was markedly lower, whereas water intake and stereotyped behavior was greater. We found that RNAi group rats presented opposite tendencies. Together, these data indicate that α-synuclein knockdown alleviates METH-induced abnormal behavior in rats.

The chemical structure of METH is similar to dopamine, allowing it to enter dopamine axons, to be released with dopamine from synaptic vesicles into the cytoplasm and to undergo reverse transport into the synaptic cleft. Indeed, several investigations have affirmed that dopamine plays a critical role in the mechanisms of METH neurotoxicity. Death of neuronal cell bodies occurs in METH-treated rat striatum (Jayanthi et al., 2005). In the present study, dopamine levels in striatum were notably lower in the model group rats than in controls, consistent with previous reports (Fukumura et al., 1998; Cappon et al., 2000; Chapman et al., 2001; Truong et al., 2005; Yue et al., 2012). Tyrosine hydroxylase activity, as a rate-limiting factor, can regulate dopamine synthesis. Decreased tyrosine hydroxylase activity is observed in the METH-induced PD rat model (Hotchkiss et al., 1979; Hotchkiss and Gibb, 1980; Morgan and Gibb, 1980). α-Synuclein co-localizes with tyrosine hydroxylase (Perez et al., 2002), suggesting that α-synuclein plays a critical role in the adjustment of dopamine biosynthesis by reducing tyrosine hydroxylase activity. Previous results also show that overexpression of α-synuclein causes cellular oxidative stress and generates a 30--80% reduction of nigral dopaminergic neurons and a 40--50% depletion of striatal dopamine (Kirik et al., 2002). In the present study, striatal dopamine levels were significantly elevated in RNAi group rats after METH treatment. To reveal the mechanism of α-synuclein knockdown on dopamine levels, we measured tyrosine hydroxylase activity, and found significantly greater striatal tyrosine hydroxylase activity in RNAi group rats compared with model group rats. These data indicate that knockdown of α-synuclein protects against METH-induced deficits in striatal dopamine and tyrosine hydroxylase activity.

Treatment with multiple high doses of METH can induce oxidative damage, including formation of dopamine-mediated reactive oxygen species, which may lead to the neurotoxic damage of monoamine neurons and long-lasting deficit of dopamine in the striatum. In the present study, abundant production of reactive oxygen species was observed after METH treatment. It was previously shown that nitrogen monoxide is involved in METH-induced neurotoxicity because the nitric oxide synthase inhibitors *Nw*-nitro-L-arginine and monomethyl-L-arginine attenuated METH-induced cell death (Sheng et al., 1996). Studies also have shown that the selective neuronal nitric oxide synthase inhibitor 7-nitroindazole was able to protect against METH-induced dopamine and 5-HT deficit in the striatum (Di Monte et al., 1996; Itzhak and Ali, 1996; Ali and Itzhak, 1998). Previous reports also indicate larger METH-induced elevation in neuronal nitric oxide synthase activity (Imam et al., 2005). In the present study, we found that the nitrogen monoxide levels and nitric oxide synthase activity in the striatum were notably elevated after METH administration. Nitrogen monoxide has the ability to react with superoxide radicals to generate the powerful oxidant and primary neurotoxin, peroxynitrite (Pacher et al., 2007). Nitric oxide synthase-related effects on α-synuclein may play an important role in PD. For example, inducible nitric oxide synthase and neuronal nitric oxide synthase associated with PD can increase the aggregation polymorphisms of α-synuclein. In the present study, α-synuclein knockdown in the striatum attenuated the elevated expression of reactive oxygen species induced by METH. In addition, both nitrogen monoxide level and nitric oxide synthase activation in the striatum were significantly lower in RNAi group rats than in model group rats after METH treatment.

Several investigations have revealed that METH is able to activate oxidative stress by changing the balance between reactive oxygen species products and the ability of antioxidant enzyme systems to clear reactive oxygen species (Kobeissy et al., 2008; Li et al., 2008). Dysfunction of the antioxidative stress system could cause reduced elimination of free radicals, leading to lipid peroxidation and severe cell and tissue damage (Kessler et al., 2003). Malondialdehyde, a product of lipid peroxidation by reactive oxygen species, is commonly used as a marker of oxidative damage (Kessler et al., 2003), and treatment with multiple high doses of METH increases malondialdehyde reactivity in the striatum of humans and experimental animals. In the present study, a remarkably elevated level of malondialdehyde was observed in the striatum of model group rats compared with control rats. Superoxide dismutase is an essential enzyme, clearing superoxide free radicals from aerobic organisms and protecting against the toxic effect of oxygen free radicals. In our experiment, superoxide dismutase activity was markedly lower in the striatum of model group rats compared with that of control group rats. Generation of stable oligomers and oxidative modifications of α-synuclein are involved in the neurotoxicity of oxidative stress (Norris et al., 2003). Here, we found that malondialdehyde expression in the striatum was significantly lower and superoxide dismutase activity was much greater in RNAi group rats compared with model group rats. Together, these data suggest that suppression of α-synuclein expression can rescue the balance between reactive oxygen/nitrogen species and antioxidant enzyme systems, which is damaged in the rat striatum treated with METH. Cell apoptosis or death is the ultimate consequence after METH treatment. Here, the ratio of neuronal apoptosis was greater in the striatum of model group rats compared with the control group rats, whereas it was markedly lower in RNAi group rats compared with model group rats.

In summary, we have shown that knockdown of α-synuclein expression markedly attenuates METH-induced oxidative stress, improves dopaminergic system deficits and increases neuronal cell viability in the rat striatum. Based on the above data, we suggest that the development of clinical α-synuclein knockdown may represent a potential approach for the treatment of PD.
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